Intrinsic Mechanism of Anticancer Drugs in Neurodegenerative Disorders

Neurodegenerative (NDDs) disorders are one of the most alarming medical illnesses

affecting the brain and nervous system. The Lack of understanding of the disease-leading

mechanisms makes the treatment options unavailable. Currently, an estimated 35.6 million

people are surviving with Dementia, and the number is presumed to triple by the next 30

years [1]. According to the report of the World Health Organization (WHO), in the next 20

years, NDDs affecting motor functions will be the second most widespread reason for

human death [2]. NDDs are categorized based on clinical features- dementia, parkinsonism,

or motor neuron disease, or based on the anatomic areas covered- spinocerebellar

degeneration, frontotemporal degeneration and extrapyramidal disorders. In general,

synucleinopathies, and TDP-43 proteinopathies are the most

widespread NDDs. Abnormal protein aggregation is the major hallmark feature of all

NDDs associated with some fundamental processes such as progressive neuronal loss,

neuroinflammation, dysfunction of the Ubiquitin proteasome system (UPS), abnormal

autophagic processes, oxidative insult, and neuronal apoptosis

(HD), and Multiple sclerosis (MS) are the major NDDs affecting the global health.

Aging is the biggest risk factor for various diseases, from cancer to NDDs. These agerelated

diseases can be categorized into two groups. Loss-of-function diseases like NDDs

are represented by the loss of cells, tissues, or optimal physiological functions. While gainof-

function diseases like cancer exhibit gain of cells and, sometimes, new cellular functions